

# **Diagnosis of Campylobacter Infection In Cases With Diarrhea**

Thesis

Submitted for Partial Fulfillment of M.Sc. Degree  
in Clinical and Chemical Pathology

**By**

**Marwa Ali Ahmed Badwi**

M.B., B.Ch.

Faculty of Medicine - Ain Shams University

**Supervised by**

**Professor / Nevine Nabil Kassem**

Professor of Clinical and Chemical Pathology,  
Faculty of Medicine - Ain Shams University

**Doctor / Samia Abdou Girgis**

Assistant Professor of Clinical and Chemical Pathology,  
Faculty of Medicine - Ain Shams University

**Doctor / Samar Saad Rashad**

Lecturer of Clinical and Chemical Pathology,  
Faculty of Medicine - Ain Shams University

**Faculty of Medicine,  
Ain-Shams University  
2011**

# تشخيص عدوى الكامبيلوبكتر فى مرضى الاسهال

## رسالة

توطئة للحصول على درجة الماجستير فى الباثولوجيا الإكلينيكية والكيميائية

### مقدمة من

الطبيبة/مروة على احمد بدوى  
بكالوريوس الطب و الجراحة  
كلية الطب- جامعة عين شمس

### تحت اشراف

## الأستاذ الدكتور / نيقين نبيل قاسم

أستاذ الباثولوجيا الإكلينيكية و الكيميائية  
كلية الطب- جامعة عين شمس

## الدكتور/سامية عبده جرجس

أستاذ مساعد الباثولوجيا الإكلينيكية و الكيميائية  
كلية الطب- جامعة عين شمس

## الدكتور / سمر سعد رشاد

مدرس الباثولوجيا الإكلينيكية و الكيميائية  
كلية الطب- جامعة عين شمس

كلية الطب  
جامعة عين شمس

٢٠١١

## Summary and conclusion

Campylobacter (curved rod in Greek) may have been first discovered in the late nineteenth century (1886) by Theodor Escherich who observed it in the colon of infants who died of a disease, he named “cholera infantum” (**Bhunja, 2008**). Currently, of the 19 Campylobacter species/subspecies that have been classified, 10 or 11 have well-established associations with animal or human diseases (**Gilbreath et al., 2011**).

Campylobacter is a major food borne pathogen of animal origin, prominently associated with poultry and is responsible for a significant percentage of intestinal infectious diseases in human in the developed world and in developing countries. It is associated mainly with illness in children. In industrialized countries, sporadic cases of human infection are generally attributed to the consumption of raw or undercooked poultry meat whereas outbreaks have been traced to contamination of the water supply and the consumption of contaminated raw milk (**Peterson, 2003 and Jeon et al., 2010**).

The incidence of human campylobacteriosis increased exponentially during the last decade of the 20th century, although part of this increase can be attributed to better

detection of Campylobacter and better diagnosis (**Smith and Bayles, 2006**).

Campylobacteriosis is a self-limited disease and antimicrobial therapy is not generally indicated. However, treatment can reduce the duration and the severity of illness if it is initiated early in the course of infection (**Coker et al., 2002 and Adekunle et al., 2009**).

Campylobacter infection represents a significant and persistent public health problem, with approximately 10 % of cases requiring hospital treatment. Sequelae that may accompany illness, such as reactive arthritis, toxic megacolon and autoimmune-mediated demyelinating neuropathies (e.g Guillain-Barré and Miller Fisher syndromes) have been added to the disease burden (**Gillespie et al., 2006**).

Because poultry, livestock, pets, and wild animals are the major reservoir for Campylobacter, control is based on interruption of transmission to humans from animals, animal products, or environmental sources contaminated by animals (**Humphrey and Jørgensen, 2006**).

The identification of Campylobacter using conventional methods is slow (culture-based methods can take up to five days) and problematic due to their fastidious growth requirements and biochemical inertness. Moreover, the detection of *C. coli* and/or *C. jejuni* in complex substrates like

faeces or environmental samples is difficult as the culture conditions have to be selective enough to avoid overgrowth from competing organisms. PCR has provided a reliable tool to detect and to quantify *C. jejuni* and/or *C. coli* in pure culture, in poultry, milk, or water, and in complex substrates like food products and faecal samples (**Maridor et al., 2011**).

A number of simple and rapid identification and discrimination methods based on the PCR have been developed for thermophilic campylobacters on the basis of genetic diversity. Alternatively, multiplex PCR for targeting several species-specific genes have also been developed (**Persson and Olsen, 2005**).

Accurate identification of *Campylobacter* species, particularly *C. jejuni*, *C. coli* and *C. fetus*, provides important data for diagnosis and proper treatment, drug of choice for severe *Campylobacter* infection, epidemiologic surveillance and risk assessment studies (**Asakura et al., 2008**).

In the current study, 50 stool samples were collected from patients suffering from diarrhea with fever, headache, abdominal pain, myalgia, vomiting and/or blood in stool. The samples were subjected to Physical examination, microscopic examination, and culture on Skirrow's media with phenotyping by Hippurate test in addition to genotyping by PCR technique.

In the present study, *Campylobacter* was isolated on Skirrow's media from 6/50 (12%) stool samples obtained from patients with sensitivity, specificity, PPV and NPV of 100%. The 4/6 samples were identified as *Campylobacter jejuni* (Hippurate test +ve). The PCR confirmed the 6 positive samples as *Campylobacter*. Also, PCR identified the 4/6 Hippurate +ve test as *C. jejuni* and 2/6 Hippurate –ve test were identified as *C. coli* with sensitivity, specificity, PPV and NPV of 100%.

Our results revealed a highly significant association between the results of the Skirrow's media and PCR ( $P < 0.001$ ); also between all the risk factors and positive stool culture cases for *Campylobacter* (2 *C. jejuni* associated with type of food and 1 *C. coli* associated with contact with birds). A highly significant association between *Campylobacter* positive cases with fever (4/5 cases were due to *C. jejuni*) was found. Stool WBC  $\geq 50$  was significantly associated with stool culture positive cases

# List of Contents

<b>Title</b>	<b>Page No.</b>
<b>List of figures .....</b>	<b>I</b>
<b>List of tables .....</b>	<b>III</b>
<b>List of abbreviations .....</b>	<b>V</b>
<b>Introduction and aim of the work .....</b>	<b>1</b>
<b>Review of Literature .....</b>	
<b>Chapter 1: Historical Overview .....</b>	<b>4</b>
<b>Chapter 2: Classification of Campylobacter species and related taxa .....</b>	<b>7</b>
<b>Chapter 3: Epidemiology .....</b>	<b>18</b>
<b>Chapter 4: Pathogenesis of Campylobacter.....</b>	<b>33</b>
<b>Chapter 5: Clinical significance of Campylobacter ...</b>	<b>48</b>
<b>Chapter 6: Laboratory diagnosis of Campylobacter infection .....</b>	<b>59</b>
<b>Chapter 7: Treatment &amp; Antimicrobial Susceptibility</b>	<b>86</b>
<b>Chapter 8: Control and Prevention .....</b>	<b>98</b>
<b>Materials and Methods .....</b>	<b>105</b>
<b>Results .....</b>	<b>124</b>
<b>Discussion .....</b>	<b>138</b>
<b>Summary .....</b>	<b>145</b>
<b>Recommendations .....</b>	<b>149</b>
<b>References .....</b>	<b>151</b>
<b>Arabic Summary .....</b>	<b>—</b>

## List of Figures

<b>No.</b>	<b>Title</b>	<b>Page No.</b>
<b>1</b>	Sources of Campylobacter infection .....	<b>21</b>
<b>2</b>	The total number of Campylobacter cases in the European Union until 2003 .....	<b>26</b>
<b>3</b>	Mechanism of Campylobacter pathogenesis in the intestine .....	<b>36</b>
<b>4</b>	The structure and function of Cytolethal distending toxin (CDT) .....	<b>40</b>
<b>5</b>	The glycosylation of flagellar and periplasmic proteins.....	<b>46</b>
<b>6</b>	Morphology of Campylobacter .....	<b>62</b>
<b>7</b>	A membrane filtration technique .....	<b>67</b>
<b>8</b>	Practical algorithm for identifying campylobacter spp. ....	<b>72</b>
<b>9</b>	Mechanisms associated with Campylobacter resistance to macrolide and fluoroquinolone antibiotics .....	<b>92</b>
<b>10</b>	Sodium hippurate hydrate test	<b>117</b>
<b>11</b>	PCR detection of lpxA gene	<b>121</b>
<b>12</b>	Morphology of Campylobacter colonies .....	<b>125</b>
<b>13</b>	Gram stained film shows Campylobacter morphology .....	<b>126</b>

<b>14</b>	Types of the identified Campylobacter species ...	<b>127</b>
<b>15</b>	The frequency of the associated symptoms of the 50 studied cases .....	<b>129</b>
<b>16</b>	Association of accompanied symptoms with stool culture positive and negative cases .....	<b>131</b>
<b>17</b>	ROC (Receiver operator characteristic) curve for stool WBC as a test for Campylobacter Infection (Considering stool culture as a golden test) .....	<b>132</b>
<b>18</b>	Association of sampling time with stool culture positive and negative cases. IQR: Interquartile range .....	<b>134</b>

## List of Tables

<b>No.</b>	<b>Title</b>	<b>Page No.</b>
<b>1</b>	Host association of Campylobacter species and pathogenesis to humans. ....	<b>17</b>
<b>2</b>	Selective media for isolation of Campylobacter .....	<b>69</b>
<b>3</b>	Biochemical properties of Campylobacter species ...	<b>76</b>
<b>4</b>	Ingredients of the master mix .....	<b>112</b>
<b>5</b>	Diagnostic performance of Skirrow's media .....	<b>127</b>
<b>6</b>	Association of risk factors for diarrhea with stool culture positive and negative cases .....	<b>128</b>
<b>7</b>	Association of accompanied symptoms with stool culture positive and negative cases .....	<b>130</b>
<b>8</b>	Value of stool WBC as a test for Campylobacter Infection .....	<b>131</b>
<b>9</b>	Association of stool WBC with stool culture positive and negative cases .....	<b>133</b>
<b>10</b>	Characteristics of stool WBC $\geq 50$ as a test for Campylobacter Infection .....	<b>133</b>
<b>11</b>	Association of stool characteristics with stool culture positive and negative cases .....	<b>135</b>
<b>12</b>	Comparison between stool culture positive and	<b>135</b>

negative cases as regards age and sex .....	
<b>13</b> Association of immunity impairing medical condition with stool culture positive and negative cases .....	<b>136</b>
<b>14</b> Association of onset and course of the diarrhea with stool culture positive and negative cases .....	<b>137</b>

## List of Abbreviations

<b>AFLP</b> .....	Amplified fragment length polymorphism
<b>AIDP</b> .....	Acute inflammatory demyelinating polyneuropathy
<b>AIDS</b> .....	Acquired Immune Deficiency Syndrome
<b>AMAN</b> .....	Acute motor axonal neuropathy
<b>AMSAN</b> .....	Acute motor-sensory axonal neuropathy
<b>ATP</b> .....	Adenosine triphosphate
<b>BAPs</b> .....	Blood agar plates
<b>C.</b> .....	Campylobacter
<b>CA</b> .....	Campylobacter agar
<b>CAMPs</b> .....	Cationic antimicrobial peptides
<b>cAMP</b> .....	cyclic adenosine monophosphate
<b>Campylobacter spp.</b>	Campylobacter species
<b>CAT medium</b>	Cefoperazone , Amphotericin B, and Teicoplanin medium
<b>CCDA</b> .....	Charcoal cefoperazone deoxycholate agar medium
<b>CDC</b> .....	Center for Disease Control and Prevention
<b>CDT</b> .....	Cytolethal distending toxin
<b>CFU</b> .....	Colony forming unit
<b>Cia</b> .....	Campylobacter invasion antigens
<b>CLSI</b> .....	Clinical and Laboratory Standards Institute
<b>CPS</b> .....	Capsular polysaccharide
<b>CSM</b> .....	Charcoal-based selective medium
<b>ECM</b> .....	Extracellular matrix
<b>Fn</b> .....	Fibronectin
<b>GBS</b> .....	Guillain–Barré Syndrome

<b>HIV</b> .....	Human Immunodeficiency Virus
<b>HL antigens</b> .....	Heat labile antigens
<b>HSP</b> .....	Heat-shock proteins
<b>IAH</b> .....	Indoxyl acetate hydrolysis
<b>LOS</b> .....	Lipooligosaccharide
<b>LPS</b> .....	Lipopolysaccharide
<b>MAMA</b> .....	Mismatch amplification mutation assay
<b>mCCDA</b> .....	Modified charcoal cefoperazone deoxycholate agar
<b>MIC</b> .....	Minimum inhibitory concentration
<b>MLS<sub>B</sub></b> .....	Macrolide lincosamide and streptogramin B
<b>MLST</b> .....	Multilocus sequence typing
<b>MSCRAMMs</b> ..	Microbial surface components recognizing adhesive matrix molecules
<b>PCR</b> .....	Polymerase chain reaction
<b>PFGE</b> .....	Pulsed field gel electrophoresis
<b>pgl</b> .....	Protein glycans
<b>PMN</b> .....	Polymorphonuclear leukocytes
<b>QRDR</b> .....	Quinolone resistance-determining region
<b>RFLP</b> .....	Restriction fragment length polymorphism
<b>T3SS</b> .....	Type III secretion system
<b>TMAO</b> .....	Trimethylamine oxide
<b>TSI</b> .....	Triple sugar iron agar
<b>US</b> .....	United States
<b>V fetus</b> .....	Vibrio fetus

## INTRODUCTION

Campylobacter is widely acknowledged as one of the most frequent pathogens causing acute bacterial gastroenteritis worldwide. Campylobacter jejuni and Campylobacter coli are the predominant cause of Campylobacteriosis. Furthermore Campylobacter fetus, Campylobacter lari and Campylobacter upsaliensis have also been recognized as human pathogens causing gastroenteritis and/or septicemia (*Matsune et al., 2007*).

Campylobacter jejuni (C. jejuni) causes an acute diarrheal disease with a variety of clinical symptoms, such as fever, diarrhea, headache, abdominal pain, myalgia, vomiting, and blood in stool (*Haddad et al., 2009*).

Campylobacter infection represents a significant and persistent public health problem, with approximately 10 % of cases requiring hospital treatment. Sequelae that may accompany illness, such as reactive arthritis, toxic megacolon and autoimmune-mediated demyelinating neuropathies (e.g Guillain-Barré and Miller Fisher syndromes) have been added to the disease burden (*Gillespie et al., 2006*). This has emphasized the need for more rapid and efficient detection methodologies than the slow and complicated process of detecting Campylobacter by culture-based techniques (*Olsen et al., 2009*).

Conventional diagnostic methods utilizing a combination of culture and biochemical testing require that suspected stool specimens are cultured on selective agar at 42°C under microaerophilic conditions for up to 72 hours before a negative report is issued (*Al Amri et al., 2007*).

A number of phenotypic and molecular typing methods are used to identify outbreak-associated *Campylobacter* strains in specific food-borne or waterborne outbreaks (*Forbes et al., 2009*). The ability to distinguish between *Campylobacter* species is important in the identification of *Campylobacter* sources and transmission routes. The PCR assays that distinguish between one or more combinations of the thermotolerant *Campylobacter* species have been described (*Klena et al., 2004*).

Erythromycin was the first macrolide to treat *Campylobacter* infections and it remains the treatment of choice for patients with uncomplicated enteritis in many countries. Also tetracycline was used for many years for treatment of humans infected with *C.jejuni* and *C.col* (*Gu et al., 2009*).

The resistance of *C. jejuni* to a range of antibiotics is common throughout the world and is thought to have been driven by the frequent use of antibiotics in animals farmed for meat. The genetic basis for antimicrobial drug resistance is known, and its spread by recombination has been demonstrated both within *C. jejuni* and between related species (*Wilson et al., 2009*).